National Natural Science Foundation of China(Grant No.21362021);Inner Mongolia Natural Science Foundation(Grant No.2015MS0206)
As Bortezomib and Carfilzomib are approved to treat refractory multiple myeloma, 20 S proteasome has become a highly interested tumor therapeutic target. Because of drug resistance of Bortezomib and Carfilzomib, β-la...